Nkarta (NKTX) vs Oramed Pharmaceuticals (ORMP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed Nkarta (NKTX) over the past year, gaining 76.2% versus a gain of 10.2%. Over five years, ORMP leads with a -80.2% price change compared with -87.6% for NKTX. Oramed Pharmaceuticals is the larger company by market cap ($174.7 million vs $158.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NKTX | ORMP |
|---|---|---|
| Share price | $2.21 | $4.20 |
| Market cap | $158.29M | $174.71M |
| 1-day change | -2.64% | -3.89% |
| YTD return | +22.70% | +53.33% |
| 1-year return | +10.19% | +76.21% |
| 5-year return | -87.62% | -80.19% |
| P/E ratio (TTM) | — | 1.02 |
| EPS (TTM) | $-1.58 | $4.13 |
| Dividend yield | 0.00% | 5.71% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.72 | $5.47 |
| 52-week low | $1.70 | $2.09 |
| Distance from 52-week high | -40.59% | -23.22% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +390.05% | +66.67% |
| Average volume | 617.86K | 192.76K |
| Shares outstanding | 71.62M | 41.60M |
| Employees | 106 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed NKTX by 66.0 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (5.71% vs 0.00%).
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
NKTX vs ORMP FAQ
Which is bigger, Nkarta or Oramed Pharmaceuticals?
Oramed Pharmaceuticals (ORMP) is larger, with a market capitalization of $174.71M compared with $158.29M for Nkarta (NKTX).
Which stock has performed better over the past year, NKTX or ORMP?
ORMP returned +76.21% over the past 12 months, compared with +10.19% for NKTX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Nkarta or Oramed Pharmaceuticals?
Oramed Pharmaceuticals pays a dividend yielding 5.71%, while Nkarta does not currently pay a regular dividend.
Are Nkarta and Oramed Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.